Highlights COMPASS Pathways plc

Equities

CMPS

US20451W1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-28 pm EDT			5-day change	1st Jan Change
7.44 ^USD	-0.53%		-5.46%	-14.97%

May. 22	Clarify Pharma confirms name change to File Forge	AN
May. 09	Transcript : COMPASS Pathways plc - Shareholder/Analyst Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Clarify Pharma confirms name change to File Forge	May. 22	AN
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Compass Pathways plc Reports Top-Line Results from an Open-Label Phase 2 Study Evaluating the Safety and Tolerability of Investigational COMP360 Psilocybin Treatment in 22 Patients with Post-Tail Stress Disorder	May. 08	CI
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement to Inform the Training of Healthcare Providers and Delivery Model for Comp360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression	Apr. 29	CI
Clarify Pharma to change name to File Forge Technology	Apr. 17	AN
ADRs End Lower; NuCana Slides 15%	Mar. 28	DJ
COMPASS Pathways plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
COMPASS Pathways plc Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Compass Pathways plc Enters into Research Collaboration Agreement with Hackensack Meridian Health to Develop Optimal Clinical Model for Investigational Comp360 Psilocybin Treatment, If FDA-Approved	Jan. 16	CI
Compass Pathways, Greenbrook TMS Start Research Collaboration on Psilocybin Treatment	Jan. 05	MT
Compass Pathways plc and Greenbrook TMS Inc. Jointly Announce They Enter into Three-Year Research Collaboration Agreement to Explore Delivery Models for Investigational COMP360 Psilocybin Treatment Upon Regulatory Approval by U.S. Food and Drug Administration	Jan. 05	CI
COMPASS Pathways plc Announces Chief Financial Officer Changes	Dec. 07	CI
COMPASS Pathways plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Compass Pathways plc Announces Executive Changes, Effective November 3 ,2023	23-10-26	CI
COMPASS Pathways plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Compass Pathways Says US Patent Office Upheld Its COMP360 Patents	23-06-06	MT
Numinus Wellness to Research COMP360 Psilocybin Therapy In Treatment-resistant Depression As Part of Large Phase 3 Study	23-05-30	MT
Compass Pathways plc Announces Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of Comp360 Psilocybin Therapy to Be Presented At Asco 2023	23-05-26	CI
COMPASS Pathways plc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
COMPASS PATHWAYS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	23-02-28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights COMPASS Pathways plc

Equities

CMPS

US20451W1018

Highlights

Filters